Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Non-Current AssetsPayablesPreferred SharesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Crescent Biopharma (CBIO) Operating Leases (2020 - 2025)

Crescent Biopharma (CBIO) has disclosed Operating Leases for 5 consecutive years, with $1.2 million as the latest value for Q4 2025.

  • Quarterly Operating Leases changed N/A to $1.2 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $1.2 million through Dec 2025, changed N/A year-over-year, with the annual reading at $1.2 million for FY2025, N/A changed from the prior year.
  • Operating Leases for Q4 2025 was $1.2 million at Crescent Biopharma, down from $1.3 million in the prior quarter.
  • The five-year high for Operating Leases was $1.7 million in Q1 2021, with the low at $66844.0 in Q4 2023.
  • Average Operating Leases over 4 years is $868849.7, with a median of $918607.0 recorded in 2021.
  • The sharpest move saw Operating Leases crashed 91.9% in 2022, then soared 174.16% in 2023.
  • Over 4 years, Operating Leases stood at $918607.0 in 2021, then plummeted by 89.59% to $95613.0 in 2022, then plummeted by 30.09% to $66844.0 in 2023, then soared by 1708.69% to $1.2 million in 2025.
  • According to Business Quant data, Operating Leases over the past three periods came in at $1.2 million, $1.3 million, and $1.6 million for Q4 2025, Q3 2025, and Q2 2025 respectively.